Tackling metabolic disorders with non-coding RNAs
Resalis Therapeutics is dedicated to developing RNA-based therapies that tackle the root causes of complex metabolic disorders.
June 22-25, 2026, San Diego, CA
With its deep expertise in non-coding RNA and lipid metabolism, Resalis Therapeutics is advancing RES-010 as a safe, effective, and disease-modifying therapy, offering sustained weight loss and improved metabolic health.
Backed by robust preclinical data, RES-010 is currently being evaluated in a Phase 1 clinical trial, positioning Resalis Therapeutics as a key company in the evolving landscape of obesity treatment.
Lead Program
RES-010, a non-coding RNA drug candidate designed to treat metabolic diseases.
We applied our deep understanding of metabolic diseases and the ncRNA modality to develop our lead candidate, RES-010. We are advancing RES-010 toward clinical evaluation initially in obesity and fatty liver disease.
